News

Number of news items returned: 41 to 60 records of 411

Support Management Solutions: Updates on Board and Development

27 February 2018

(5837 views)

    Support Management Solutions: Updates on Board and Development   "New Director Hugh Hamilton has been appointed to the Board. Hugh has experience in ...

Happy New Year - Funding Strategies Connect Jan 2018

06 February 2018

(4775 views)

    Happy New Year - Funding Strategies Connect Jan 2018   Dear Readers, Happy new year!   Flora Mok and myself were privileged to attend the ...

Squirrel Acquires London Based FCA Licensed Financial Service

05 February 2018

(4369 views)

    Squirrel Acquires London Based FCA Licensed Financial Service   "Squirrel Limited through its wholly owned UK based subsidiary, Squirrel Money Limited is ...

Mark's report on his recent Hong Kong visit

01 February 2018

(4593 views)

    Flora Mok and myself (pictured above) were privileged to attend the Asian Financial Forum, the Asia Private Equity Forum and ...

Dealer Trade Progress Report

25 January 2018

(3615 views)

    Dealer Trade has provided a progress report in regards to: Gumtree - CarRecord Partnership New Manufacturer - Suzuki QLD Dealer Trade UK Fairfax - ...

AqMB offers "PFD export to CAD software, smartPFD mode, plant rollback & simplified stream numbering"

25 January 2018

(3885 views)

    AqMB offers "PFD export to CAD software, smartPFD mode, plant rollback & simplified stream numbering"   Transition easily from BFD to PFD ...

"Support Management Solutions to raise capital for new medical software product"

23 January 2018

(4801 views)

    "Support Management Solutions to raise capital for new medical software product   Support Management Solutions to seek capital in 6-9 months to ...

2017 - its a wrap! Funding Strategies Connect December 2017

19 December 2017

(6754 views)

  2017 - its a wrap! Funding Strategies Connect December 2017     Dear Readers, 2017 - its a wrap! We have completed significant assignments for ...

Squirrel ranked 84th in the 2017 Deloitte Technology Fast 500 awards

18 December 2017

(6840 views)

  "Fresh off the back of Squirrel's recognition as one of the AFR's Fast Starters, I am pleased to announce we ...

Opmantek named 55th Australian Export Awards category winner

15 December 2017

(6557 views)

  Opmantek named  55th Australian Export Awards category winner     On the back of winning the 4th consecutive Queensland Premier's Export Award, Opmantek ...

BlueMount Capital Secures Major Debt Funding

07 December 2017

(6759 views)

    BlueMount Capital Secures Major Debt Funding   "In conjunction with BlueMount Capital’s Melbourne office, I am delighted to announce we have secured ...

"Walking over broken glass for sustainability"

06 December 2017

(6186 views)

    "Walking over broken glass for sustainability"   "Dr Ho’s team, along with industry partners Brisbane City Council and EnviroSand, are investigating mixtures ...

Squirrel recognised in the 2017 AFR Fast Starters List

09 November 2017

(5764 views)

  Squirrel recognised in the 2017 AFR Fast Starters List   Squirrel debut's on the Australian Financial Review's Fast Starters list, as the ...

The market, introductions and news - Funding Strategies Connect October 2017

31 October 2017

(6451 views)

    Dear Reader,   It's an interesting time in the capital markets space at the moment. Australia has seen a large initial coin offering ...

"CaroMel's platform launch set"

27 October 2017

(5782 views)

"CaroMel's platform launch set   Platform launch CaroMel’s platform is ready for launch. The company will now sprint to load the branding and ...

"We are launching any day now" CaroMel Ltd Podcast

19 October 2017

(6006 views)

    "We are launching any day now"   Podcast: Listen as Raghu Rajakumar spoke to Greg McLardie, Managing Director of CaroMel Ltd. CaroMel is ...

LeenLife signs Agreement with BioCube

17 October 2017

(6077 views)

  LeenLife Pharma International: Production and Operations in North America Exclusivity Agreement with BioCubeTM   "October 17, 2017 CSE - LLP The Company is pleased to ...

Mining, Cars and Cyber Protection - Funding Strategies Connect September 2017

06 October 2017

(5405 views)

  Dear Reader,   In discussing our services with prospects and clients, it is important to be clear on their company's strategic objectives. Quite ...

CaroMel - Director Briefing with Greg McLardie

03 October 2017

(6029 views)

  Director Briefing with Greg McLardie, CaroMel Ltd   “Our digital platform allows orders to be received from and shipped directly to the ...

Haixi - Extension of the Offer Period

28 September 2017

(5983 views)

  Haixi - Extension of the Offer Period   "The Board of Directors of Haixi Pharmaceutical International Holdings Limited (ACN 616 806 574) ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625